Rexahn Pharmaceuticals is a biopharmaceutical company based in Germantown, MD, dedicated to developing innovative therapies for cancer treatment. With a focus on radiation oncology and immuno-oncology, their groundbreaking products aim to cure cancer and enhance patient outcomes by sensitizing cancer cells, protecting normal tissues, and monitoring clinical responses to treatment.
Driven by a world-class team of scientific, clinical, and regulatory experts, including co-founders Dr. Anatoly Dritschilo, Dr. Milton Brown, and Dr. Mira Jung, Rexahn Pharmaceuticals has built a robust platform technology for the discovery and development of novel small molecules. Through strategic collaborations and a portfolio of lead clinical-stage and pre-clinical products, they are at the forefront of advancing the field of radiation oncology and revolutionizing cancer therapy.
Generated from the website